title: Tertiary hyperparathyroidism after high-dose phosphate therapy in adult-onset hypophosphatemic osteomalacia.
abstract: OBJECTIVE
  To describe a case of adult-onset hypophosphatemic osteomalacia treated with orally administered phosphate and complicated by tertiary hyperparathyroidism.
  
  
  METHODS
  We present pertinent clinical, radiologic, and laboratory details of the study patient for a period of more than 20 years and discuss the few reported cases of tertiary hyperparathyroidism attributable to prolonged phosphate therapy.
  
  
  RESULTS
  A 49-year-old Jordanian man, who had been diagnosed at age 26 years as having sporadic adult-onset hypophosphatemic vitamin D-resistant osteomalacia, presented with severe right hip pain, severe osteopenia with lytic bone lesions, and hypercalcemia after prolonged oral treatment with phosphate and vitamin D. These clinical, radiologic, and biochemical findings, in conjunction with a very high serum parathyroid hormone level, indicated the diagnosis of tertiary hyperparathyroidism, which was substantiated histopathologically.
  
  
  CONCLUSIONS
  Physicians should be aware of the potential for development of tertiary hyperparathyroidism in patients receiving prolonged oral phosphate therapy.
authors.affiliation: National Center for Diabetes, Endocrinology and Genetics, P.O. Box 13165, Amman 11942, Jordan.
authors.forename: E
authors.initials: E
authors.lastname: Younis
authors.forename: N
authors.initials: N
authors.lastname: Jarrah
authors.forename: A S
authors.initials: AS
authors.lastname: Sroujieh
authors.forename: A
authors.initials: A
authors.lastname: Al Hadidy
authors.forename: K
authors.initials: K
authors.lastname: Ajlouni
mesh_terms: D000469:Alkaline Phosphatase / Q000097:blood; D001706:Biopsy; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000473:pathology / Q000503:physiopathology; D002112:Calcifediol / Q000097:blood; D006801:Humans; D006934:Hypercalcemia / Q000209:etiology; D006961:Hyperparathyroidism / Q000175:diagnosis / Q000209:etiology* / Q000601:surgery; D017674:Hypophosphatemia / Q000150:complications / Q000188:drug therapy*; D007597:Jordan; D008279:Magnetic Resonance Imaging; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D018908:Muscle Weakness; D010018:Osteomalacia / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D010146:Pain; D016105:Parathyroidectomy; D010710:Phosphates / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D010758:Phosphorus / Q000097:blood; D011859:Radiography; D014807:Vitamin D / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D010710:Phosphates; D014807:Vitamin D; D010758:Phosphorus; D000469:Alkaline Phosphatase; D002112:Calcifediol